Skip to main content
OpenTrials
Completed

NCT Number: NCT01425268

Patient Controlled Tissue Expansion for Breast Reconstruction

This study is designed to compare the performance and safety of the AirXpander tissue expander to standard saline expanders in patients undergoing two-stage breast reconstruction following mastectomy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Marin General Hospital, Greenbrae, California, United States

Loading trial locations.

About this study

This is a pivotal, prospective, multi-center randomized, controlled, open-label clinical study designed to compare the performance and safety of the AirXpander Tissue Expander System to currently cleared saline tissue expanders. Subject who meet the inclusion and agree to participate in the study will be enrolled and randomized to either the investigational arm (AirXpander Tissue Expander) or the control arm (standard saline tissue expander) using a 2:1 (AirXpander to saline) permuted block randomization stratified by investigational center and procedure (unilateral or bilateral). If the subject is having a bilateral procedure, the same type of expander will be implanted in each side. Subjects in both arms will be followed in the same manner until the explantation of the tissue expander(s) and exchange for permanent implant(s).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is a woman between the ages of 18-70.
  • Subject needs to have tissue expansion as part of her breast reconstruction.
  • Subject is able to provide written informed consent.
  • Subject is able and willing to comply with all of the study requirements.
  • Subject is able to understand and manage at home dosing regimen.

Exclusion criteria

  • Subjects skin is not suitable for tissue expansion.
  • Subject has remaining tumor cells following her mastectomy.
  • Subject has a current or prior infection at the intended expansion site.
  • Subjects skin has been damaged by previous radiation treatments and the use of non radiated tissue from another part of her body will not be used.

4a. Subject had planned radiation therapy at the intended expansion site while the expander is implanted.

  • Subject has a history of failed tissue expansion or breast implantation at the intended expansion site.
  • Subject has any existing medical condition that the doctor thinks puts the subject at an increased risk of complications (e.g., severe collagen vascular disease, poorly managed diabetes).
  • Subject is taking any medications that the doctor thinks puts the subject at an increased risk of complications (e.g., prednisone, Coumadin).
  • Subject is currently participating in a concurrent investigational drug or device study.
  • Subject is a current tobacco smoker. 10. Subject is overweight (BMI > 33). 11. Subject is unwilling to comply with the air travel or altitude restriction of not > 3300 feet (1000 meters) from baseline during the time the AeroForm tissue expander is implanted.
  • Subject has a currently implanted electronic device such as a pacemaker, defibrillator, neurostimulator device, or drug infusion device.
  • Subject is pregnant or planning on becoming pregnant during the study period.
  • Subject has a history of psychological condition, drug or alcohol misuse which may interfere with their ability to use the device safely.

Treatment and study plan

AeroForm Tissue Expansion

Device

The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.

Other names: AirXpander Tissue Expander System, Patient Activated Controlled Expansion (PACE), AeroForm Patient Activated Tissue Expander, AeroForm Tissue Expander System, AeroForm Tissue Expander

Saline Tissue Expansion

Procedure

A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.

Other names: saline breast tissue expander, saline expander, breast tissue expander, tissue expander

Primary outcomes

  1. Successful Tissue Expansion and Exchange to a Permanent Breast Implant Unless Precluded by a Non-device Related Event

    Time frame: 12 months

    The primary endpoint is assessed when the subject has completed tissue expansion and completed an exchange to standard breast implants. Subjects not completing the exchange procedure due to a device related event are considered failures.

Secondary outcomes

  1. Expansion Days

    Time frame: 12 months

    The median number of days taken to complete the expansion process.

Sponsors and collaborators

Lead sponsor

AirXpanders, Inc.

Industry

Registry information

Official study title

AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction

Acronym: XPAND

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Aug 30, 2011
Registry last updated
Jun 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.